WILLIAMS ROBERT M JR sold $192.6M of AVAH (indirect holdings)

WILLIAMS ROBERT M JR sold 16,750,002 indirectly-held shares of Aveanna Healthcare Holdings, Inc. (AVAH) at $11.50 ($192.63M total) across 6 trades over 2026-08-20 to 2026-08-21.

Original reporting
SEC EDGAR · WILLIAMS ROBERT M JR
Published Aug 24, 2026, 10:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 24, 2026, 10:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AVAH
Bearish
high confidence
Mentioned
$AVAH
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AVAHBearishMed
01

Why it matters

A $192M insider sell is sizable for a mid‑cap healthcare company and can influence short‑term price dynamics.

02

Market read

The filing is a primary source of new material information that may affect AVAH's stock price in the near term.

03

What to watch

The sale was executed via multiple trades at a consistent $11.50 price, possibly indicating a pre‑arranged liquidity need rather than negative outlook.

Relevance 8/10Novelty 8/10Timing: post‑market 2026‑08‑20

Background

Form 4 filings provide the first public disclosure of insider transactions, offering timely insight into insider sentiment.

Company-level read

Ticker impact

$AVAHBearishHigh confidence
Context

10% owner Robert M. Williams Jr. sold 16.75M shares (~$192.6M) in AVAH, reducing his stake to ~12.3M shares.

Expected impact

Possible short‑term downside pressure; traders may consider defensive positions.

Evidence & confidence

The sale represents a material portion of the insider's holdings and is disclosed via a primary Form 4 filing, making it a fresh, material event.

Market effects

May raise concerns for the healthcare services sector if other insiders follow suit.

Limited to U.S. markets where AVAH trades.

Minimal global impact beyond AVAH investors.

Counterpoint

Insider could be diversifying; the sale does not necessarily reflect company fundamentals.

Key entities

  • Aveanna Healthcare Holdings, Inc.

    Ticker AVAH, provider of home health and hospice services.

  • Robert M. Williams Jr.

    10% owner of AVAH who executed the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AVAHHighAI 8/10

Aveanna Healthcare Earnings Call Signals Broader Growth, Higher Guidance

Aveanna Healthcare (AVAH) reported Q3 revenue of $695.5M, up 11.8%, and adjusted EBITDA of $100.1M, up 25%. All segments grew, with Home Health and Hospice up 15.6%, Private Duty Services up 11.6%, and Medical Solutions up 9.1%. The company raised 2026 guidance to revenue above $2.695B and adjusted EBITDA above $374M, citing growth in preferred payers and state rate enhancements. Management highlighted caregiver shortages and California rate uncertainty as risks.

$AVAHMedAI 8/10

What Aveanna Healthcare (AVAH) Said on Its Q3 Earnings Call

Aveanna Healthcare (AVAH) reported Q3 revenue growth of 15.6% to $72.1M in Home Health and Hospice, and 9.1% to $49.2M in Medical Solutions. CEO Shaner cautioned that 20-25% growth is unsustainable. The company secured $30M in California funding for rate increases, aiming for permanency. Aveanna reconfirmed long-term growth targets and plans to focus acquisitions on Home Health and Hospice. It reported $492M in liquidity and $1.52B in variable-rate debt, all hedged through 2029.

$AVAHHigh

Raymond James reiterates Strong Buy on Aveanna stock after beat

Raymond James reiterated a Strong Buy rating and $15.00 price target for Aveanna Healthcare (AVAH) after its Q3 2026 results beat estimates. AVAH reported adjusted EBITDA of $100.1M, 7.5% above consensus, and raised its 2026 EBITDA guidance to at least $374M. The stock trades at $13.09, with 13% upside to the target. RBC Capital increased its price target to $16.00, citing positive market positioning.